Related Experiment Videos
Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease
A Erikson1, M Aström, J E Månsson
1Department of Pediatrics, County Hospital Boden, Sweden.
Insights
Enzyme infusion therapy improved well-being and normalized health markers in eight patients with Norrbottnian Gaucher disease (type 3). This treatment is recommended for type 3 Gaucher disease, showing potential for neurological benefits.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Gaucher disease (GD) is a lysosomal storage disorder.
- Norrbottnian type (GD type 3) is a rare subtype.
- Enzyme replacement therapy (ERT) is a treatment option.
Purpose of the Study:
- To evaluate the efficacy of enzyme infusion therapy in patients with Norrbottnian Gaucher disease.
- To assess clinical, hematological, and neurological outcomes.
- To explore biomarkers for monitoring treatment response.
Main Methods:
- Enzyme infusion therapy administered to eight GD type 3 patients (ages 4-42).
- Clinical assessments included physical well-being, organ size, growth, and neurological status.
- Biochemical analysis of circulating glucosylceramide levels.
Main Results:
- All patients showed improved well-being, reduced liver and spleen size, and normalized hematological parameters.
- Children experienced catch-up growth; no further neurological deterioration was observed, with some signs of improvement.
- Circulating glucosylceramide levels, a potential dosage monitoring parameter, responded better in non-splenectomized patients.
Conclusions:
- Enzyme infusion therapy is effective in managing GD type 3.
- The therapy leads to significant clinical improvements and potential neurological benefits.
- Monitoring glucosylceramide levels may aid in optimizing ERT dosage.
Abstract:
We report our experience from enzyme infusion therapy of eight patients with the Norrbottnian type of Gaucher disease (type 3) aged 4 to 42 years. All patients responded with increased well-being, decreased liver and spleen size and normalized hematological parameters. The children caught up in growth. No further neurological deterioration occurred and there were some indications of neurological improvement. Circulating glucosylceramide concentrations seemed to be a possible parameter to monitor the dosage of infused enzyme. The circulating glucosylceramide levels responded better in non-splenectomized patients. Enzyme infusion therapy can be recommended in type 3 Gaucher disease.